Interestingly, when focused on those 339 patients who were scored as HER2 2~3+ according to BC/GEA criteria and then determined by DSISH, the clinicopathological feature distribution in these 339 patients showed that HER2 amplification was positively associated with tumor invasion, lymphatic metastasis, and advanced TNM staging. This evidence concerns the gene ERBB2 and breast cancer.